In advanced refractory cholangiocarcinoma, where FGFR2 fusions predominate2, the reversible FGFR1–FGFR3 inhibitor pemigatinib5 and the irreversible FGFR1–FGFR4 inhibitor futibatinib are approved for tumors with FGFR2 fusions or other rearrangements7. Here, FGFR1 is linked to cholangiocarcinoma.